-
AbbVie Grants Enigma Biomedical Group Rights to Next-Generation PET Imaging Biomarkers
•
AbbVie (NYSE: ABBV), a leading pharmaceutical company in the US, has licensed to Canada-based Enigma Biomedical Group (EBG) its cutting-edge F18 PET imaging biomarkers. These biomarkers are designed to detect the presence of four-repeat (4R) tau protein in patients who may have neurodegenerative diseases. The agreement holds potential for aiding…
-
Sichuan Health Commission Issues Directive to Strengthen Oversight of External Prescriptions
•
The Health Commission of Sichuan Province has issued a notification aimed at enhancing the management of ex-hospital allocation prescriptions at medical institutions. Ex-hospital allocation prescriptions are those written for drugs not available within the hospital’s inventory during hospitalization, outpatient, or emergency treatment, or prescribed at the request of patients. After…
-
Shaanxi Panlong Pharmaceutical Partners with Xi’an Medical University for Multifaceted Collaboration
•
Shaanxi Panlong Pharmaceutical Group Co., Ltd (SHE: 002864), a leading pharmaceutical company based in China, has announced the signing of a cooperation framework agreement with Xi’an Medical University. This strategic partnership will see the two entities leveraging their respective resources to collaborate across various fields. Under the agreement, Panlong Pharma…
-
Tasly Pharmaceuticals Gets NMPA Go-Ahead for Clinical Trial of Stem Cell Therapy in Heart Failure
•
Tasly Pharmaceuticals (SHA: 600535), a leading pharmaceutical company in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with a clinical study for its human umbilical cord mesenchymal stem cell injection, B2278. The study aims to evaluate the efficacy of this therapy…
-
Sinocelltech Granted NMPA Approval for Phase I Clinical Trial in Hematological Malignancies
•
Sinocelltech Group Ltd (SHA: 688520), a biopharmaceutical company based in China, has announced that it has received clearance from the National Medical Products Administration (NMPA) to initiate a Phase I clinical study for its monoclonal antibody SCTC21C, targeting CD38+ hematological malignant tumors. This development marks a significant step forward in…
-
Sanofi’s Dupixent Receives FDA Label Update for Atopic Dermatitis Patients with Hand or Foot Involvement
•
Sanofi (NASDAQ: SNY) has been granted authorization by the US Food and Drug Administration (FDA) to update the label of Dupixent (dupilumab) to include efficacy and safety data for patients aged 12 and older with atopic dermatitis that involves uncontrolled moderate-to-severe hand or foot symptoms. The data from a late-stage…
-
Luzhu Biotechnology’s LZ901 Herpes Zoster Vaccine Trial Fully Enrolls 26,000 Participants
•
Beijing Luzhu Biotechnology Co., Ltd (HKG: 2480), a leading manufacturer of human vaccines and therapeutic biologics, has declared the successful completion of patient enrollment for the Phase III clinical study of its vaccine candidate LZ901 in China. Over 98% of the participants have received the requisite two doses of either…
-
Danaher Corporation to Establish Northern China Headquarters in Beijing’s Changping District
•
The Changping District People’s Government of Beijing Municipality has entered into a strategic cooperation agreement with Danaher Corporation (NYSE: DHR), a leading science and technology services provider based in the United States. The agreement encompasses the establishment of Danaher’s northern China headquarters in the district, along with the development of…
